Business
Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs
All amounts are in US dollars QUÉBEC CITY, March 28, 2014 /CNW Telbec/ - Aeter...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\nAll amounts are in US dollars\n\n\nQUÉBEC CITY, March 28, 2014 /CNW Telbec/ - Aeterna Zentaris Inc.\n (NASDAQ: AEZS) (TSX: AEZ) (the \"Company\") today announced that its\n shelf registration statement on Form F-3 previously filed with the\n Securities and Exchange Commission (the \"SEC\") has been declared\n effective by the SEC. Under the shelf registration statement, the\n Company may offer and sell from time to time, in one or more public\n offerings in the United States, up to $50 million of common shares in\n one or more \"at-the-market\" (\"ATM\") distribution programs, during a\n 36-month period. The specifics of any particular ATM share issuance\n program, along with the terms and the use of proceeds of any such\n common shares offered by the Company will be determined at the time of\n any such offering and will be described in detail in a prospectus\n supplement or supplements filed with the SEC at the time of any such\n offerings.\n\n\nThis press release and the prospectus are not an offer to sell these\n securities and they are not soliciting an offer to buy these securities\n in any jurisdiction where the offer or sale is not permitted. You\n should not assume that the information contained in the prospectus and\n the accompanying prospectus supplement is accurate on any date\n subsequent to the date set forth on the front of these documents or\n that any information that the Company has incorporated by reference is\n correct on any date subsequent to the date of the document incorporated\n by reference. The Company's business, financial condition, results of\n operations and prospects may have changed since those dates.\n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a specialty biopharmaceutical company engaged in\n developing novel treatments in oncology and endocrinology. The\n Company's pipeline encompasses compounds at various stages of\n development. For more information, visit www.aezsinc.com.\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements made pursuant to\n the safe harbour provisions of the U.S. Securities Litigation Reform\n Act of 1995. Forward-looking statements involve known and unknown risks\n and uncertainties that could cause the Company's actual results to\n differ materially from those in the forward-looking statements. Su...